Robert D. Sindelar
University of British Columbia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Robert D. Sindelar.
Archive | 2007
Daan J.A. Crommelin; Robert D. Sindelar; Bernd Meibohm
It sounds good when knowing the pharmaceutical biotechnology fundamentals and applications third edition in this website. This is one of the books that many people looking for. In the past, many people ask about this book as their favourite book to read and collect. And now, we present hat you need quickly. It seems to be so happy to offer you this famous book. It will not become a unity of the way for you to get amazing benefits at all. But, it will serve something that will let you get the best time and moment to spend for reading the book.
Archive | 2013
Robert D. Sindelar
The products resulting for biotechnologies continue to grow at an exponential rate, and the expectations are that an even greater percentage of drug development will be in the area of the biologics. In 2011, worldwide there were over 800 new biotech drugs and treatments in development including 23 antisense, 64 cell therapy, 50 gene therapy, 300 monoclonal antibodies, 78 recombinant proteins, and 298 vaccines (PhRMA 2012). Pharmaceutical biotechnology techniques are at the core of most methodologies used today for drug discovery and development of both biologics and small molecules. While recombinant DNA technology and hybridoma techniques were the major methods utilized in pharmaceutical biotechnology through most of its historical timeline, our ever-widening understanding of human cellular function and disease processes and a wealth of additional and innovative biotechnologies have been, and will continue to be, developed in order to harvest the information found in the human genome. These technological advances will provide a better understanding of the relationship between genetics and biological function, unravel the underlying causes of disease, explore the association of genomic variation and drug response, enhance pharmaceutical research, and fuel the discovery and development of new and novel biopharmaceuticals. These revolutionary technologies and additional biotechnology-related techniques are improving the very competitive and costly process of drug development of new medicinal agents, diagnostics, and medical devices. Some of the technologies and techniques described in this chapter are both well established and commonly used applications of biotechnology producing potential therapeutic products now in development including clinical trials. New techniques are emerging at a rapid and unprecedented pace and their full impact on the future of molecular medicine has yet to be imagined.
Canadian Journal of Chemistry | 1981
James P. Kutney; Gary M. Hewitt; Toshio Kurihara; Phillip J. Salisbury; Robert D. Sindelar; Kenneth L. Stuart; Philip M. Townsley; William T. Chalmers; Giulio G. Jacoli
Archive | 2008
Daan J.A. Crommelin; Robert D. Sindelar; Bernd Meibohm
Heterocycles | 1980
James P. Kutney; Michael H. Beale; Phillip J. Salisbury; Robert D. Sindelar; Kenneth L. Stuart; Brian R. Worth; Phillip M. Townsley; William T. Chalmers; Danielle J. Donnelly; Kristina Nilsson; Giulio G. Jacoli
Journal of Chromatography A | 1981
James P. Kutney; Robert D. Sindelar; Kenneth L. Stuart
The American Journal of Pharmaceutical Education | 2009
Gary M. Oderda; J. Chris Bradberry; Pamela U. Joyner; Eric J. Mack; Ruth E. Nemire; Robert D. Sindelar; William E. Smith; Robert Soltis; Cecilia M. Plaza
Pharmaceutical patent analyst | 2012
Örn Almarsson; Mauro Angiolini; Jonathan B. Baell; Giuseppe Giardina; Andrew Ingham; Adam Hughes; Paolo Pevarello; Robert D. Sindelar
Archive | 2009
Gary M. Oderda; PharmD; J. Chris Bradberry; Pamela U. Joyner; EdD; Eric J. Mack; Ruth E. Nemire; Robert D. Sindelar; William E. Smith; Robert Soltis; Cecilia M. Plaza
Archive | 2007
Daan J.A. Crommelin; Robert D. Sindelar; Bernd Meibohm